Renal, Endocrine, and Bone Changes in Response to Treatment With Coformulated Emtricitabine-Tenofovir for Pre-Exposure HIV Prophylaxis (PrEP) in HIV Uninfected Young Men Who Have Sex With Men
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- 15 Nov 2016 Results assessing the relative importance of renal and endocrine changes in tenofovir disoproxil fumarate related bone toxicity, published in the Clinical Infectious Diseases.
- 29 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.